COCRYSTAL FORMS OF ((1S,2S,4R)-4-{4-[(1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO]-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL}-2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE, FORMULATIONS AND USES THEREOF

The present invention is directed to cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate of formula (I). The invention is also directed to methods of making cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate of formula (I). The invention is also directed to the pharmaceutical use of a cocrystal form as an E1 activating enzyme inhibitor, as well as a pharmaceutical composition comprising a cocrystal form. The invention is further directed to a method of treatment comprising administering a cocrystal form of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate of formula (I). La présente invention concerne des formes co-cristallines de ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-indén-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)méthylsulfamate de formule (I). L'invention concerne également des procédés de fabrication de formes cocristallines de ((1S,2S,4R)-4-{4- [(1S)-2,3-dihydro-1H-indén-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)méthylsulfamate de formule (I). L'invention concerne également l'utilisation pharmaceutique d'une forme co-cristalline à titre d'inhibiteur d'enzyme d'activation E1, ainsi qu'une composition pharmaceutique comprenant ladite forme co-cristalline. Une méthode de traitement comprenant l'administration d'une forme co-cristalline de ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-indén-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)méthylsulfamate de formula (I) est en outre décrite.